Laguna Niguel, CA, United States of America

Elizabeth WoldeMussie

USPTO Granted Patents = 18 

 

Average Co-Inventor Count = 2.7

ph-index = 10

Forward Citations = 451(Granted Patents)


Company Filing History:


Years Active: 1996-2013

Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents

Title: Elizabeth WoldeMussie: Innovator in Pharmaceutical Compositions

Introduction

Elizabeth WoldeMussie is a prominent inventor based in Laguna Niguel, CA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of eye disorders. With a total of 18 patents to her name, her work has had a profound impact on medical science.

Latest Patents

Among her latest patents, one focuses on pharmaceutical compositions and methods for treating dry eye disorders. This invention highlights the use of inhibitors of Janus kinase-3 (Jak3) as effective treatments for dry eye disorders. The specific compound detailed in her patent is 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile. Another significant patent outlines methods for treating retinal diseases, providing neuroprotection to mammals at risk of nerve cell injury or death. This method involves administering a compound that targets specific positions on the quinoxaline nucleus to inhibit noxious actions resulting from ischemia.

Career Highlights

Elizabeth has worked with notable companies such as Allergan, Inc. and Allergan Sales, Inc. Her career has been marked by a commitment to advancing pharmaceutical research and developing innovative treatments for eye-related disorders.

Collaborations

Throughout her career, Elizabeth has collaborated with esteemed colleagues, including Guadalupe Ruiz and Joseph S. Adorante. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Elizabeth WoldeMussie stands out as a leading inventor in the pharmaceutical industry, particularly in the realm of eye care. Her innovative patents and collaborations reflect her dedication to improving treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…